| Summary: | Made available in DSpace on 2014-06-11T19:27:20Z (GMT). No. of bitstreams: 0
Previous issue date: 2009-02-09Bitstream added on 2014-06-13T18:31:20Z : No. of bitstreams: 1
pavan_fr_me_arafcf.pdf: 465333 bytes, checksum: a257ef7f9c510b42345a93dc770ca838 (MD5) === Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) === Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) === O Mycobacterium tuberculosis, principal agente da tuberculose (TB), é responsável pela morte anual de dois a três milhões de pessoas no mundo e por prejuízos econômicos globais de aproximadamente 12 bilhões de dólares ao ano. Estima-se que 1/3 da população mundial esteja infectada com o bacilo na forma latente. Apesar disso, nenhuma nova droga específica contra o M. tuberculosis foi desenvolvida desde 1960. O presente trabalho objetivou a investigação do potencial anti-M. tuberculosis intra e extracelular juntamente com a citotoxicidade de 66 compostos envolvendo diferentes classes de ligantes como tiossemicarbazonas, semicarbazonas, hidrazonas, diiminas, fosfinas e bases de Schiff, juntamente com dois diferentes metais (vanádio e rutênio) formando diferentes e inéditos complexos. Para as diferentes análises biológicas in vitro, 3 técnicas já padronizadas foram utilizadas para a detecção da Concentração Inibitória Mínima (CIM), da Citotoxicidade (IC50) e da Atividade Intracelular. Dos 66 compostos analisados neste trabalho, 7 complexos contendo o rutênio, cis-[RuCl2(NO)(BPA)] (G1), cis- [Ru(pic)(dppe)2]PF6 (G6), [Ru(pic)(dppb)(bipy)]PF6 (G7), [Ru(pic)(dppb)(Mebipy)] PF6 (G8), [Ru(pic)(dppb)(Cl-bipy)]PF6 (G9), [Ru(pic)(dppb)(fen)] (G12), cis-[RuCl2(dppb)(bipy)] (G14), foram qualificados como potenciais agentes anti- TB, porque apresentaram atividade inibitória melhor do que algumas drogas comumente utilizadas no tratamento da tuberculose, baixa citotoxicidade e alta atividade inibitória intracelular. === The Mycobacterium tuberculosis, the major agent of tuberculosis (TB), is responsible for approximately 2-3 million deaths annually, with a global economic injury of approximately $12 billion per year. It is estimated that 1/3 of the worldwide population are infected with the latent form bacilli. Although, no new specific drug against M. tuberculosis was developed since 1960. The objective of this study was the investigation of intra and extracellular anti-M. tuberculosis activity and cytotoxicity of 66 compounds involving different class of ligants as thiosemicarbazones, semicarbazones, hydrazones, diimines, phosphines and Schiff bases with two different metals (vanadium and ruthenium) resulting different and unknown complexes. For the different biologicals in vitro analyses, three standardized techniques had been used for the detection of the Minimal Inhibitory Concentration (MIC), Cytotoxicity (IC50) and Intracellular Activity. Of 66 compounds analyzed in this study, 7 complexes containing the ruthenium, cis-[RuCl2(NO)(BPA)] (G1), cis-[Ru(pic)(dppe)2]PF6 (G6), [Ru(pic)(dppb)(bipy)]PF6 (G7), [Ru(pic)(dppb)(Me-bipy)]PF6 (G8), [Ru(pic)(dppb)(Cl-bipy)]PF6 (G9), [Ru(pic)(dppb)(fen)] (G12), cis- [RuCl2(dppb)(bipy)] (G14), were qualified as potential anti-TB agents, because they presented inhibitory activity better than some drugs commonly used in the TB treatment, low cytotoxicity and high intracellular inhibitory activity.
|
|---|
